abbvie


abbvie
AbbVie (NYSE: ABBV) is a global, research-based biopharmaceutical company. AbbVie develops and markets advance therapies that address some of the world’s most complex and serious diseases. AbbVie products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. AbbVie has also a pipeline of promising new medicines, including more than 50 compounds or indications in clinical development across such important medical specialties as immunology, virology/liver disease, oncology, neurological diseases, and women’s health. AbbVie became independent publicly traded company, which is currently a Fortune 200 company traded on the New York Stock Exchange, on January 1, 2013, as a result of the distribution by Abbott Laboratories of 100 percent of outstanding common stock of AbbVie to Abbot’s shareholders.
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas.
